Affimed reorganises management team

Affimed Therapeutics, a German therapeutic TandAb antibody company, has reorganised its management team under the leadership of Adi Hoess and Rolf Guenther.

Hoess, previously chief commercial officer, is now chief executive, while Guenther, previously chief executive, is now chief operating officer with a focus on advancing the pipeline through clinical trials.

"With a platform technology allowing development of multiple product candidates it is now time to adapt the organisation to the new needs,’ said Thomas Hecht, chairman of Affimed.

‘I am confident that under the leadership of Adi with his extensive business background in commercial operations and M&A strategies and with Rolf focusing on the clinical development of our core assets and overseeing the operations we have set up the company not only to build on its assets but also to prepare for its future.’